Egetis Therapeutics AB (publ) (0ABW.L)

5.94 -0.91 (-13.28%) At close: 05:10PM BST

Egetis Therapeutics AB (publ)

Klara Norra Kyrkogata 26
Stockholm 111 22
Sweden
46 86 79 72 10
https://www.egetis.com

Sector(s): 
Industry: 
Full-time employees: 28

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nicklas Westerholm	Chief Executive Officer	4.8M	N/A	1976
Mr. Torsten Almén	Founder	N/A	N/A	N/A
Dr. Ingemar Lundström Ph.D.	Founder	N/A	N/A	1943
Dr. Louis Joseph Ignarro Ph.D.	Founder	N/A	N/A	1942
Associate Prof. Heidi Brurok	Founder	N/A	N/A	N/A
Dr. Rob Towart	Founder	N/A	N/A	N/A
Dr. Yilmaz Mahshid Ph.D.	Chief Financial Officer	N/A	N/A	1979
Dr. Katayoun Welin-Berger Ph.D.	Vice President of Operations	N/A	N/A	1968
Dr. Jacques Näsström M.B.A., MBA, Ph.D.	Chief Scientific Officer	655k	N/A	1959
Dr. Karl Hard Ph.D.	Head of IR & Business Development	N/A	N/A	1962

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Corporate governance

Egetis Therapeutics AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.